

1. General data

Schneider, Rebekka K., Univ.-Prof. Dr. Dr.

***18.11.1981 (f)**

2. Scientific education

2007 State board examination in Medicine, Germany
2001-2007 Medical School RWTH Aachen University, Aachen Germany

3. Academic degrees

2017 PhD Thesis, Department of Hematology, Erasmus MC Cancer Institute, the Netherlands; disputation *cum laude* (highest distinction in NL)
2008 Medical Doctoral Thesis, Institute of Pathology, RWTH Aachen University; disputation *summa cum laude*

4. Scientific positions

2020 Professor and Chair of Cell and Tumor Biology, University Hospital RWTH Aachen
2018 Associate Professor, Department of Hematology, Erasmus MC Cancer Institute
2016-2017 Assistant Professor, Department of Hematology, Erasmus MC Cancer Institute
2017-2020 Principal Investigator, Department of Hematology, RWTH Aachen University, Aachen, Germany; Max Eder Research Group leader
2012-2015 Postdoctoral Research Fellow, Department of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (lab Benjamin L. Ebert, MD, PhD)
2008-2011 Postdoctoral Research Fellow & Fellowship Pathology, Institute of Pathology, RWTH Aachen University

5. Other (function in editorial or advisory board, honors and awards)

Honors and Awards: Proof-of-Concept grant "deAlarmin" European Research Council (ERC); Swammerdam Award Dutch Hematology Association; Starting grant "deFIBER" ERC; Johann Georg Zimmermann Award; Innovationspreis Deutsche Hochschulmedizin; Artur Pappenheim Award, Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Tito Bastianello Award of the International Society for Myelodysplastic Syndromes.

Invited lectures: n>100 including key-note lectures at the German, Dutch, European and American Society of Hematology, European School of Hematology, Harvard Stem Cell Institute

6. Selected publications

1. Gleitz H, Dugourd AJF, Leimkühler NB, Snoeren IAM, Hoogenboezem R, Bindels E, Schumacher N, Rose-John S, Elf S, Saez-Rodriguez J, Kramann R, **Schneider RK**. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. **Blood** **2020**; 136(18): 2051-2064.
2. Leimkühler NB, Gleitz HFE, Ronghui L,Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Wing-Ying E, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG and **Schneider RK**. Heterogeneous bone marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis; **Cell Stem Cell** Dec 9;S1934-5909(20)30542-7. doi: 10.1016/j.stem.2020.11.004.
3. **Schneider RK#**, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira MS, Puellas V-G, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R#. Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. **Cell Stem Cell** **2018**; 23(2): 308-309. *#corresponding author*
4. **Schneider RK**, Schenone M, Ventura Ferreira M, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8/S100A9. **Nature Medicine** **2016**; 22(3): 288-97.
5. **Schneider RK**, Adema V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. **Cancer Cell** **2014**; 26(4): 509-20.